未登录

L

Long-Yun Ye

fudan university

H指数:25

被引数:2,106

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mucosal-Associated Invariant T (MAIT) cells in the Tumor Microenvironment: Opportunities and Challenges

肿瘤微环境中的黏膜相关恒定T（MAIT）细胞：机遇与挑战

Critical Reviews in Oncology/Hematology

IF0

2026-04-280

PRE

Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation

神经源性诱导剂通过促进肿瘤细胞转分化来抑制胰腺癌的增殖。

Journal of Experimental & Clinical Cancer Research

IF12.8

2025-11-180

OAAI

Ferroptosis Pathway Discrimination and Anticancer Therapeutic Screening Enabled by Cascade-Activated Fluorescence Reporting of Cysteine-Viscosity Dynamics

胱氨酸-粘度动力学级联激活荧光报告驱动的 ferroptosis 通路区分及抗癌治疗筛选

Analytical Chemistry

IF6.7

2025-11-050

PRE

Genomic mutation and Clinicopathological features of KRAS wild-type tumors in Chinese cohort with pancreatic adenocarcinoma

中国胰腺腺癌队列中KRAS野生型肿瘤的基因组突变和临床病理特征

IF3

2025-05-010

OAAI

The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer

CELL DEATH & DISEASE

IF9.6

2024-04-046

OAAI

Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway

ACTA BIOCHIMICA ET BIOPHYSICA SINICA

IF3.4

2024-01-161

OAAI

Follicle-stimulating hormone orchestrates glucose-stimulated insulin secretion of pancreatic islets

NATURE COMMUNICATIONS

IF15.7

2023-11-0110

OAAI

Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma

IF10.1

2023-11-017

PRE

Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma

IF4.2

2023-06-100

PRE

Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer

胰腺癌中致癌改变诱导的脂质代谢重编程的新策略

ACTA BIOCHIMICA ET BIOPHYSICA SINICA

IF3.4

2023-04-062

OAAI

Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2023-02-218

OA

Innate immunity in pancreatic cancer: Lineage tracing and function

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-01-166

OAAI

Focus on mast cells in the tumor microenvironment: Current knowledge and future directions

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

IF8.3

2023-01-0118

PRE

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer

COM33通过抑制Twist1抑制卵巢癌中卡铂诱导的上皮间质转化

ACTA BIOCHIMICA ET BIOPHYSICA SINICA

IF3.4

2022-12-223

OAAI

Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-09-2620

OAAI

Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer

IF10.8

2022-05-0117

OAAI

The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy

JOURNAL OF NEUROENDOCRINOLOGY

IF4.1

2022-04-052

PRE

SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer

IF10.1

2022-04-0128

PRE

Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors

ENDOCRINE PRACTICE

IF4.6

2022-03-013

PRE

LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells

ACTA BIOCHIMICA ET BIOPHYSICA SINICA

IF3.4

2021-12-2318

OAAI